No Association Between Genetic Polymorphisms in NAD(P)H Oxidase p22phox and Paraoxonase 1 and Colorectal Cancer Risk

ELISE M.J. VAN DER LOGT1, CYNTHIA H.J.M. JANSSEN1, ZAIRAH VAN HOOIDONK1, HENNIE M.J. ROELOFS1, THEO WOBBES2, FOKKO M. NAGENGAST1 and WILBERT H.M. PETERS1

Departments of 1Gastroenterology and 2Surgery, University Medical Centre St. Radboud, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands

Abstract. Background: Impaired metabolism of ingested toxic or carcinogetic compounds is a postulated mechanism underlying colorectal cancer (CRC). Furthermore, it is suggested that reactive oxygen species (ROS) may play a role in human cancer development. Polymorphic variations in NAD(P)H oxidase p22phox and paraoxonase 1 (PON1) enzyme activities may alter superoxide production or the rate of chemical metabolism, respectively, and this may influence the risk for CRC. Therefore, this study was designed to determine whether the distribution of polymorphisms in NAD(P)H oxidase p22phox and PON1 genes was different in sporadic CRC patients versus healthy controls. Materials and Methods: The study participants (365 cases and 354 controls) were all of Caucasian origin. NAD(P)H oxidase p22phox H72Y, and PON1 L55M and Q192R polymorphisms were genotyped by polymerase chain reaction, eventually followed by restriction-fragment-length-polymorphism analyses. Results: Comparison of CRC patients and controls revealed no significant differences in genotype distributions or allele frequencies for polymorphisms in the NAD(P)H oxidase p22phox and PON1 genes. Investigation of potential associations between the variant NAD(P)H oxidase p22phox or PON1 alleles and the clinical characteristics, tumour location or tumour stage, also did not reveal statistically significant associations. Conclusion: Variant genotypes of NAD(P)H oxidase p22phox and PON1 do not contribute to the susceptibility to CRC.

The aetiology of colorectal cancer (CRC) remains elusive. It is estimated that up to 10% of CRC cases can be attributed to hereditary factors of high penetrance (1), leaving approximately 90% so-called sporadic CRC cases, which may be attributed to diet (2), lifestyle factors (3, 4) and genetic factors of low penetrance (5). Genetic predisposition to CRC may involve polymorphic variations in genes encoding for detoxification enzymes. Genetic variations in these enzymes may alter the conversion rate of toxic/carcinogetic compounds ingested by food, medication or lifestyle habits (e.g. smoking), which subsequently might influence the levels of these compounds in the colonic lumen or mucosa, possibly altering the risk for CRC. In addition, it is suggested that reactive oxygen species (ROS) may also play a role in human cancer development (6-8). ROS may induce cellular changes characteristic of those produced by known carcinogens (7). Phagocytosis by polymorphonuclear leukocytes results in the release of ROS, referred to as the respiratory burst, which plays an important role in the host defence against certain microorganisms. However, excessive generation of ROS by these phagocytes may cause harm to surrounding tissue and this may influence the risk for CRC (9).

The NAD(P)H oxidase enzyme is involved in the production of large quantities of superoxide during the respiratory burst of activated phagocytes. However, not only phagocytes, but also non-phagocytic cells, such as endothelial cells, vascular smooth muscle cells, cultures of transformed colonic epithelial cells or primary colonic epithelial cells, may produce superoxide (10, 11). In non-phagocytic cells, superoxide has been suggested to act as a regulator of genes involved in proliferation, apoptosis and inflammation (12). NAD(P)H oxidase is a membrane-bound enzyme complex, which consists of a transmembrane electron transporting component, comprising a catalytic subunit cytochrome b558, consisting of gp91phox and p22phox (13). In the p22phox gene a C242T polymorphism has been identified that substitutes histidine by tyrosine at codon 72 (11). This may result in 72H homozygotes with normal enzyme activity, and heterozygotes or 72Y homozygotes both with diminished enzyme activity (14). These variations in NAD(P)H oxidase p22phox genotypes...
eventually could lead to different amounts of superoxide in the colonic lumen or mucosa, which actually may influence the risk for CRC.

Paraoxonase 1 (PON1) is an esterase that is widely distributed among tissues such as liver, kidney and intestine, but also is present in blood plasma, where it is associated with high-density lipoproteins (HDL; 15, 16). The PON family (PON1-3) enzymes are hydrolases with a broad substrate specificity (17). The PON1 protein was identified first and, therefore, has been most studied. PON1 is a phase I detoxification enzyme that hydrolyzes organophosphates, such as the insecticides paraaxon and chlorpyrifos, and nerve agents, such as sarin or soman (18). It also hydrolyzes aliphatic lactones, like dihydrocoumarin and homocysteine-thiolactone (19, 20). Furthermore, PON1 inactivates lipoxidation derivatives of low-density lipoprotein (LDL) (15, 21, 22). In summary, PON1 can offer protection against toxic environmental agents, as well as endogenous products of oxidative stress. In the PON1 gene two common functional polymorphisms, L55M and Q192R, have been described, both of which may affect serum paraoxonase activity. PON1-55L is correlated with higher PON1 activity and mRNA levels than PON1-55M (23, 24), possibly caused by a decreased stability of the PON1-55M protein (25). The Q192R polymorphism results in substrate-dependent differences in the kinetics of hydrolysis of various substrates. The PON1-192R allele is associated with a higher activity to hydrolyze paraaxon, whereas the efficiency to hydrolyze sarin, diazoxon or lactones was lower compared with the PON1-192Q allele (18, 26). In addition, the Q192R polymorphism also alters the ability of the enzyme to protect LDL from oxidation, the PON1-192Q allele being most protective (27). Since PON is a HDL-associated enzyme, many studies have investigated the relationship between PON1 polymorphisms and coronary heart disease (28) and atherosclerosis (29). Although PON is also known to play a role in the detoxification of toxic/carcinogenic compounds and, therefore, may influence susceptibility to cancer, data on its association with cancer are rare. Kerridge et al. (30) were the first to demonstrate an association between PON1 polymorphisms and cancer in humans: the homozygous variant PON1-192R genotype was significantly more often present in non-Hodgkin’s lymphoma cases compared with control subjects. Furthermore, Akcay et al. found lower PON serum levels in patients with pancreatic (31) or gastric cancer (32) than in healthy controls, which suggests that PON may play a role in the aetiology of gastrointestinal cancer.

Polymorphic variations in NAD(P)H oxidase p22phox and PON1 enzymes may alter superoxide production or conversion rates of toxic/carcinogenic compounds, respectively, and this may influence the risk for CRC. Therefore, this study was designed to determine whether sporadic CRC patients have another distribution of polymorphisms in NAD(P)H oxidase p22phox and PON1 genes as compared to healthy controls.

### Materials and Methods

**Patients and control subjects.** The selection of patients and controls has been described previously (33). Briefly, the sporadic CRC group consists of 365 patients (209 males, 156 females; mean age 64±11 years) and for comparison a control group of 354 healthy subjects (144 males, 210 females; mean age 43±13 years) was recruited by advertisement in a local paper. All subjects studied were Caucasians of Dutch origin. Relevant data of the patients and controls are summarized in Table I.

**DNA isolation.** DNA was extracted from either whole blood (276 cases and 354 controls) or normal colorectal mucosa (89 cases), as
Detection of the H72Y substitution in the restriction-fragment-length-polymorphism (RFLP) analyses. The PCR product was digested with the restriction enzyme AlwII, which was 54°C for 1 min, and the PCR conditions were 4 min at 95°C, then 35 cycles of 30 sec at 95°C, 1 min at 56°C, and 1 min at 72°C, and finally an elongation step at 72°C for 5 min. Digestion of the PCR product with the restriction enzyme RsaI was followed by separation on 2% agarose. A 348-bp fragment indicates the 55M-allele and 66- and 33-bp fragments for the 72H-allele, whereas fragments of 188- and 160-bp are indicative for the 72Y-allele. The polymorphisms in the PON1 gene corresponding with amino acid substitutions at the codons 55 and 192 were determined according to Humbert et al. (34). The forward and reverse primers used for detection of the L55M substitution were: 5'-GAA GAG TGA TGT ATA GCC CCA-3' and 5'-TTT AAT CCA GAG CTA ATG AAA GCC-3', respectively. The PCR conditions were 4 min at 95°C, then 35 cycles of 30 sec at 95°C, 1 min at 56°C, and 1 min at 72°C, and finally an elongation step at 72°C for 7 min. Digestion with NlaIII resulted in a non-digested 170-bp PCR product indicative for the 55L-allele and 126- and 44-bp fragments for the 55M-allele. For detection of the Q192R substitution, we used the forward primer: 5'-TAT TGT TGC TGT GGG ACC TGA G-3' and reverse primer: 5'-CAC GCT AAA CCC AAA TAC ATC TC-3'. Except for the annealing temperature, which was 54°C for 1 min, similar PCR conditions were used as described for the detection of the L55M substitution. Digestion with AbwI yielded a non-digested 99-bp fragment indicative for the 192Q-allele and 66- and 33-bp fragments for the 192R-allele. Digested PCR products of the two PON1 polymorphisms were separated on 3% agarose and visualized using ethidium bromide. At each PCR run, sterile H2O was run in parallel with genomic DNA samples and served as a negative control for amplification.

### Statistical analyses

Differences between the characteristics of patients and controls were analyzed with the Chi-square test and t-test. A p-value below 0.05 was considered significant. All genotypes investigated among controls were tested to find out whether they were distributed according to the Hardy-Weinberg equilibrium. Chi-square statistics were used to test for differences in genotype distribution and allele frequencies between the two study groups. Odds ratios (OR) with 95% confidence interval (95% CI) were calculated by logistic regression analyses, taking into account confounding factors such as age and gender. Finally, the Spearman rank coefficient of correlation was calculated for the association between the two PON1 polymorphisms. All statistical analyses were performed using SPSS (version 12.0; SPSS Inc., Chicago, USA).

### Results

Descriptive statistics of CRC patients and controls are given in Table I. The mean age of the CRC patients (64±11 years) was higher compared to that of the control group (43±13 years; p<0.0001). Subsequently, there was a statistically significant difference in gender between the CRC patients and healthy controls, with more female subjects in the control group (p<0.0001).

For all polymorphisms investigated, the distribution of the allele frequencies among the control subjects was tested and found to be in Hardy-Weinberg equilibrium. No differences in genotype distribution were observed for the gene polymorphisms.
three polymorphisms investigated between CRC patients and controls (Table II). The allele frequencies also showed no statistical differences between the two study groups (Table III).

We also investigated potential associations between allele frequencies of the detoxification enzymes and clinical characteristics of the patients, such as tumour location and tumour stage, and the results are summarized in Table IV. These data only reveal a borderline association of the variant PON1-55M allele with distal CRC, age- and gender-adjusted OR 1.1, 95% CI 0.98-1.3. No relationship was found between allele frequencies of the investigated enzymes and tumour stage.

Finally, the co-occurrence of the PON1-55 and PON1-192 polymorphisms was investigated. A negative correlation was found in both patients ($r_s = -0.29$, $p<0.01$) and controls ($r_s = -0.37$, $p<0.01$). Thus, the PON1-55M and PON1-192Q polymorphisms, both associated with low enzyme activity, are usually linked on one allele. This combination of PON1 polymorphisms was not distributed differently between the CRC patients and healthy controls.

**Discussion**

It is generally accepted that inter-individual differences in genetic factors of low penetrance and environmental exposures may influence the risk for CRC (35). Polymorphisms in genes encoding for detoxification enzymes may be of importance in susceptibility to toxic or carcinogenic environmental chemicals (5, 36). In addition, there is increasing evidence that ROS may also play a role in human cancer development (6-8). To investigate the role of
NAD(P)H oxidase and paraoxonase enzymes in colorectal carcinogenesis, we determined the frequencies of NAD(P)H oxidase p22<sup>phox</sup> and PON1 gene polymorphisms in healthy controls and patients with sporadic CRC. The observed frequencies of the variants of p22<sup>phox</sup> and PON1 in our control population are in full agreement with the corresponding data from several other studies (14, 17, 30, 37, 38).

Perner et al. (10) concluded that superoxide, released in epithelial cells isolated from the normal human colon by NAD(P)H oxides expressing the p22<sup>phox</sup> subunit, can contribute to the maintenance of the normal colonic barrier. Knowing this, it may be hypothesized that polymorphisms in NAD(P)H oxidase p22<sup>phox</sup> can contribute to an increased risk of colon cancer, but the results of this study do not confirm this hypothesis. The p22<sup>phox</sup>-72Y homozygotes, however, may have only a diminished and not a complete loss of enzyme activity (14), and this reduced enzyme activity may still be sufficient to maintain the normal colonic barrier.

Since it has been demonstrated that polymorphisms affecting amino acid substitutions at positions 55 and 192 are associated with marked alterations of PON1 serum concentrations (23, 24), and PON1 serum levels were reported to modulate susceptibility towards other gastrointestinal cancers (31, 32), we investigated the relationship between PON1 polymorphisms and CRC. No differences were observed for genotype distributions and allele frequencies between patients and controls, except for a trend towards a slightly increased risk for distal CRC in individuals bearing the PON1-55M allele. The PON1-55M variant is associated with a reduced enzyme activity (23, 24), which could mean that the conversion rate of carcinogenic compounds is decreased and that these compounds may accumulate in the colonic lumen. Nevin et al. (16) reported that the PON1 genotype accounts for 76% of the variation in serum PON enzyme activity level. In addition, PON1 serum levels are modulated by disease state, dietary, lifestyle and environmental factors and, therefore, may vary up to 13-fold between individuals (17, 39). Moreover, human studies characterizing the PON1 polymorphisms have indicated the importance of estimating the PON1 status (i.e. genotype and phenotype taken together) rather than genotyping alone (40). Unfortunately, no serum was available from the majority of our patients, so we were unable to measure serum PON1 enzyme activities.

Our findings have to be viewed in the perspective of potential limitations. Odds ratios can only be calculated correctly when confounding factors, such as age, gender, diet and other lifestyle factors, are taken into consideration. In this study, we observed a statistically significant difference in age and gender between the CRC patients and controls. By including both age and gender in the logistic regression analyses, we corrected the calculated odds ratios for differences in these factors. This is necessary because the younger control subjects, in comparison to the CRC patients, have had a shorter time of exposure to carcinogens and, thus, at the moment they reach the age of the CRC patients, some of them may also have developed CRC. It would have been preferable to better match the control and patient populations, but in practice this was very difficult to realize. In this study, no information was available on the dietary habits, alcohol use and smoking patterns of both patients and controls, which may also be confounding factors. Possibly some of the low-penetrance genes investigated here only contribute to CRC in combination with (some of) these dietary or lifestyle factors. In conclusion, no association was found between polymorphic variations in NAD(P)H oxidase p22<sup>phox</sup> and PON1 genes and the risk for sporadic CRC.

Acknowledgements

The authors wish to thank Numico Research Netherlands for their interest and financial support.

References


Received November 24, 2004
Accepted February 2, 2005